Skip to content
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
Search
Category: Press Releases

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More
Page1 … Page431 Page432 Page433 Page434 Page435 … Page445
RECENT POSTS

2026 World Cup Leaves Mark with Record Attendance and Controversies

July 20, 2026

2026 World Cup Leaves Mark with Record Attendance and Controversies

July 20, 2026

DRC’s Neighbors Bolster Ebola Preparedness Amid Rising Cases

July 20, 2026

DRC’s Neighbors Strengthen Ebola Preparedness Amidst Rising Cases

July 20, 2026

DRC’s Neighbors Strengthen Ebola Preparedness Amidst Rising Cases

July 20, 2026

2026 World Cup: The Tournament That Changed Football Forever

July 20, 2026

2026 World Cup: The Tournament That Changed Football Forever

July 20, 2026

African Development Bank Group Allocates $13 Million for Ebola Outbreak Response in Central Africa

July 20, 2026
Copyright © 2026 Le Congo Tribune. All Rights Reserved.